The mentioned approach is frequently used in the tandem treatment of metastatic prostate cancer, where 177Lu-labeled PSMA-617 is followed by 225Ac-PSMA-617 therapy (Khreish et al. 2020). This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.